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ABSTRACT
The guanosine-adenosine-rich exonic splicing
enhancer (GAR ESE) identified in exon 5 of the
human immunodeficiency virus type-1 (HIV-1) pre-
mRNA activates either an enhancer-dependent
5’ splice site (ss) or 3’ ss in 1-intron reporter
constructs in the presence of the SR proteins
SF2/ASF2 and SRp40. Characterizing the mode of
action of the GAR ESE inside the internal HIV-1 exon
5 we found that this enhancer fulfils a dual splicing
regulatory function (i) by synergistically mediating
exon recognition through its individual SR protein-
binding sites and (ii) by conferring 3’ ss selectivity
within the 3’ ss cluster preceding exon 5. Both
functions depend upon the GAR ESE, U1 snRNP
binding at the downstream 5’ ss D4 and the E42
sequence located between these elements.
Therefore, a network of cross-exon interactions
appears to regulate splicing of the alternative
exons 4a and 5. As the GAR ESE-mediated activa-
tion of the upstream 3’ ss cluster also is essential for
the processing of intron-containing vpu/env-mRNAs
during intermediate viral gene expression, the GAR
enhancer substantially contributes to the regulation
of viral replication.
INTRODUCTION
After integration into the host genome HIV-1 gene
expression is driven by a single promoter leading to a
single primary transcript. Translational start codons can
eﬃciently inhibit downstream translation, although dis-
continuous ribosome scanning has been reported for env
translation (1,2). To allow translation of all eight viral
ORFs encoded by the primary transcript, alternative
splicing is required to remove inhibitory translational start
codons. Indeed, up to now more than 40 viral mRNA
isoforms have been described many of which only diﬀer in
their 50 untranslated regions (UTR) (3–8).
HIV-1 alternative splicing shows tight temporal regula-
tion during viral replication (9). Progressive changes in the
splicing pattern of the primary transcript shift the mRNA
pool towards isoforms with increasing intron content.
While in the early phase of viral gene expression only
1.8-kb mRNAs are generated encoding the regulatory
proteins Tat and Rev and the accessory protein Nef,
additional expression of the 4-kb Env glycoprotein
precursor mRNA is caused in the intermediate phase by
the interaction of Rev with an RNA secondary structure
(Rev Responsive Element, RRE). Finally expression of
the Gag and Gag/Pol precursors encoded by unspliced
transcripts arises in the late phase of viral gene expression
(9). It has been shown that disturbing the temporal
regulation of viral precursor mRNA splicing can inﬂuence
infectivity and pathogenesis of HIV-1 (10–12).
In the early as well as in the intermediate phase of viral
RNA processing more than 90% of the mRNAs are
spliced at one of the 30 ss A4c, A4a, A4b or A5, which
accumulate in a 30 ss cluster upstream of exon 5. The
progress from early to intermediate RNA splicing pattern
is hallmarked by the appearance of intron-containing
mRNA due to interference with splicing at 50 ss D4.
Therefore, diﬀerential activation of the 30 ss cluster
upstream of exon 5 and of the downstream ﬂanking 50 ss
D4 is crucial for the regulated expression of the viral
proteins Rev, Nef, Vpu and Env. The proteins Rev and
Nef play important regulatory roles in HIV-1 gene
expression. Rev is essential for viral replication, because
it fulﬁls the adaptor function for feeding intron-containing
HIV-1 mRNA into the CRM1-mediated export pathway.
Nevertheless, for eﬃcient viral replication the accessory
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expressed, which are encoded by mRNAs spliced at the
most distal 30 ss of the cluster A5. It has been shown
that the viral protein Nef modulates intracellular signal-
ling by binding to a number of proteins involved in
signal transduction pathways including Hck, Lyn and
Raf1 (13,14).
Although it was originally postulated that alternative
splicing of the HIV-1 pre-mRNA depends on combination
of strong 50 ss with consistently weak 30 ss (15), we found
that 30 ss with a strong intrinsic strength are also present
within the HIV-1 pre-mRNA (16). From these studies
it can be concluded that the regulation of alternative
30 ss usage in HIV-1 relies on the combination of intrinsic
weak 30 ss with enhancer elements and of intrinsic strong
30 ss with silencer elements allowing trans-mediated
alterations in splice site activation.
A number of cis-regulatory elements neighbouring
almost all splice sites of the primary transcript substan-
tially regulate alternative splicing of HIV-1 mRNAs
(11,16–24). Most of the cis-regulatory elements are located
in an exonic position with respect to the multiply spliced
class of mRNAs and were shown to regulate 30 ss usage,
although one of these regulatory elements has also been
described within an intronic position (Figure 1) (19).
The cellular eﬀectors described so far to mediate the
HIV-1 cis-regulating enhancer and silencer functions
belong to the serine-arginine rich (SR) protein family or
to the heterogeneous nuclear ribonucleoprotein particle
(hnRNP) family. According to the current model,
enhancer-bound SR proteins support splicing by stabiliz-
ing spliceosomal components at splice sites through
protein–protein interactions mediated by their arginine-
serine rich (RS) domains. HnRNP proteins bound to
silencers inhibit splicing by interfering with spliceosome
assembly in part by counteracting SR protein-mediated
stabilizing interactions. In addition to the formation of
protein–protein interactions, recent reports have shown
that the RS domains of enhancer-bound SR proteins are
also able to stabilize the binding of U1 snRNA and U2
snRNA at the 50 ss and the branch point sequence (BPS),
respectively (25,26). Subsequent work has demonstrated
that the necessity for the contact between the RS domain
and the splicing signals depends on the individual splice
site strength (27).
Previously we identiﬁed an exonic splicing enhancer
termed GAR ESE (guanosine-adenosine-rich exonic spli-
cing enhancer) in the exon 5 of HIV-1 (28), which is
targeted by the SR proteins SF2/ASF and SRp40 (22).
In an in vitro splicing assay the GAR ESE showed
comparable activation of an enhancer-dependent hetero-
logous 30 ss in the presence of either puriﬁed SF2/ASF or
SRp40. Here we further characterized the role of the GAR
enhancer for HIV-1 gene expression starting with the
investigation of the diﬀerential impact of SF2/ASF- and
SRp40-binding sites on exon recognition in a subgenomic
context preserving the exon 5 sequence including the
ﬂanking viral splice sites. We show that every two of the
three individual binding sites for SF2/ASF and SRp40
synergistically mediate the enhancer function. While the
exon recognition function of the GAR enhancer showed
no clear preference for activation by either SF2/ASF or
SRp40, we identiﬁed a novel function of the proximal
SF2/ASF-binding site of the GAR ESE in speciﬁcally
activating A5 of the alternative 30 ss cluster, which is
assisted by an additional upstream SF2/ASF-binding site.
Although the 30 ss selection was solely conferred by the
GAR enhancer, binding of U1 snRNP at the downstream
50 ss enforces selective 30 ss activation. In addition to the
GAR ESE, the presence of an additional enhancer activity
in the 30 half of exon 5 is absolutely required for
recognition of the internal exons ﬂanked by D4. The
role of the GAR enhancer is not restricted to splicing
events in the early phase of viral RNA processing, but
remains essential for activation of the 30 ss cluster during
the generation of Rev-dependent intron-containing HIV-1
mRNA.
MATERIALS AND METHODS
Oligonucleotides
Unlabelled oligonucleotides were synthesized as pre-
viously described (29). Cy5-labelled oligos #1544 and
#1225 for RT–PCR were purchased from Metabion
GmbH (Martinsried, Germany).
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Figure 1. Distribution of splicing regulatory elements in the HIV-1 pre-
mRNA. (A) Schematic depiction of the HIV-1 genome. Open reading
frames are indicated by open boxes. Flanking long terminal repeats
(LTRs) are shown as grey boxes. (B) Distribution of 50 ss (D1–D5) and
30 ss (A1–A7) within the genomic HIV-1 RNA. The position of exon 5
is indicated (dark grey box). A1A and D1A have been published to be
preferentially involved in pre-mRNA stabilization (8). The nomencla-
ture of HIV-1 splice sites refers to (50). (C) The enlargement of the
30 half of the pre-mRNA depicts the location of the known enhancer
(green) and silencer elements (red) regulating viral pre-mRNA splicing
[eM: ESEM1/M2, sV: ESSV, s2p: ESS2p, e2: ESE2, s2: ESS2, I: ISS,
e3: ESE3, s3: ESS3; adapted from (24)]. Exon 5 is ﬂanked by 50 ss D4
and 30 ss A5 and contains the GAR ESE in the 50 part. The 30 ss A4c,
A4a and A4b cluster directly upstream of exon 5.
Nucleic Acids Research, 2008, Vol. 36, No. 5 1451Oligo sequences for cloning were:
#640: 50-CAATACTACTTCTTGTGGGTTGG
#1660(SRp40
 anti-sense): 50-ATCGAGCTCTTCGTC
GCTAAATCCGCTTCT
#1737(GTV 15Asense): 50-ATCTCATGAAATGCAA
CCTATAAT
#1831: 50-AGAGCTAGCTATCTGTTTTAAAG
#1903(SF2(1)
  SF2(2)
  anti-sense): 50-ATCGAGCTCTT
AGCGCTGTCTCCGCTAATTCCTGCCGTAGGAG
#1987(SF2(1)
  anti-sense): 50-ATCGAGCTCTTCGT
CGCTGTCTCCGCTAATTCCTGCCGTAGGAG
#1988(SF2(2)
  anti-sense): 50–ATCGAGCTCTTAAG
CGCTGTCTCCGCTTC
#2000(SRp40
  SF2(2)
  anti-sense): 50-ATCGAGCTC
TTAAGCGCTAAATCCGCTTCTTCCTGC
#2067(SF2(1)
  SRp40
  anti-sense): 50-ATCGAGCTC
TTCGTCGCTAAATCCGCTAATTCCTGCCGTAGG
AG
#2499(SF2(3)
— anti-sense): 50-ATCGAGCTCTTCGT
CGCTGTCTCCGCTTCTGCCTGCCGTAGGAGAT
#2501(SF2(3)
  GARmut anti-sense): 50-ATCGAGCTC
TTAAGCGAAGTCGCCGCTAATGCCTGCCGTAGG
AGAT
#2555(cs-2
14 sense): 50-ATCGAGCTCATCAGAACA
GTCAGACTCATCAAGCTTCTCTATCAAAGAGGT
AACATCTACATGTAATGCAAC
#2556(E42 sense): 50-ATCGAGCTCGCAGTAAGT
AGTACA
#2559(HIV#18 sense): 50-ATCGAGCTCGTGGTATA
TAAAATTATTCATAATGATAGTAGGAGGCGCAG
TAAGTAGTACA
#2598(ESE
  anti-sense): 50-ATCGAGCTCTTAAGCG
CTAAATCCGCTAATTCCTGCCGTAGGAG
Oligo sequences for RT-PCR were:
#1224(30 RT–PCR primer hGH): 50-TCTTCCAGCCT
CCCATCAGCGTTTGG
#1225(50 RT–PCR primer hGH): 50-CAACAGAAATC
CAACCTAGAGCTGCT
#1542(30 RT–PCR primer): 50-CACCTTCTTCTTCTA
TTCCTT
#1543(30 RT–PCR primer): 50-CCCCCATCTCCACAA
#1544(50 RT–PCR primer): 50-CTTGAAAGCGAAAG
TAAAGC
Plasmids
Generation of the HIV-1 NL4/3 (GenBank Accession No.
M19921) derived subgenomic reporter construct pSV-1-
env and mutant derivatives pSV-1-env 3U and pSV-1-env
SF2
  SRp40
  has been described (22).
For generation of mutant constructs pSV-1-env ESE
 ,
pSV-1-env SRp40
  SF2(2)
 , pSV-1-env SF2(1)
  SRp40
 ,
pSV-1-env SF2(1)
  SF2(2)
 , pSV-1-env SRp40
 , pSV-1-
env SF2(2)
 , pSV-1-env SF2(1)
 , pSV-1-env SF2(3)
  and
pSV-1-env SF2(3)
  GARmut the EcoRI–SacI fragment of
pSV-1-env was substituted for PCR products ampliﬁed
with the 50 primer #1544 and 30 primers #2598, #2000,
#2067, #1903, #1660, #1987, #1988, #2499 or #2501,
respectively, using pSV-1-env as template.
The construct pSV-1-env cs+1
12 was generated by
substituting the SacI–NheI fragment of pSV-1-env
containing 50 ss D4 for the respective fragment of SV
E/X tat
– rev
  cs+1
12.
Substitution of D4 for 50 ss cs-2
14 in construct
pSV-1-env cs-2
14, of the E42 sequence for the HIV#18
control in pSV-1-env HIV#18 and deletion of the E42
sequence in the mutant construct pSV-1-env E42 was
performed by substitution of the SacI–NdeI fragment of
pSV-1-env for the PCR products ampliﬁed with 50 primers
#2555, #2559, or #2556, respectively, and 30 primer #1831
using pSV-1-env as substrate.
Mutant construct pSV-1-env GTV was generated by
substituting the SacI–NheI fragment of pSV-1-env with
the SacI–NheI fragment from SV E/X tat
–rev
– GT V (28).
Mutation of the cryptic 50 ss 13-nt downstream of
D4 from GT to GA was achieved by substituting the
BspHI–NdeI fragment with the PCR product ampliﬁed
with primer pair #1737/#640 using pSV-1-env as template
generating pSV-1-env GTV 15A.
The Rev expression plasmid SVcrev (30) and the U1
snRNA expression plasmids pUCBU1 9T10G11C (31),
and pUCBU1 6A (28) have already been described.
All constructs were conﬁrmed by DNA sequencing
of substituted subgenomic or PCR-ampliﬁed fragments.
Sequences of all constructs are available on request.
Cell cultureand transfection
In DMEM supplemented with 10% FCS 2 10
5
HeLa-T4
+ cells (32) were plated per 6-well 24h before
transfection. Cells were transfected with 1mg of pSV-1-env
or mutant derivatives and 1mg of pXGH5 encoding the
human growth hormone (33) to monitor transfection
eﬃciency using FuGENE
TM6 according to the manufac-
turer’s protocol (Roche Molecular Biochemicals). For
cotransfection experiments, 1mg of the respective plasmids
were used and DNA amounts were equalized with pSP73.
RNA was isolated 30h after transfection.
RNA preparation and RT–PCR
Total RNA isolation using a modiﬁed guanidinium iso-
thiocyanate protocol and RT–PCR were performed as
described before (22).
For analysis under denaturating conditions RT-PCR
products were ﬂuorochrome-labelled by using Cy5-
labelled 50 primer #1544 for alternatively spliced reporter
mRNA or #1225 for hGH-mRNA. Separation and detec-
tion were performed by Automated Laser Fluorescence
(ALF) using a DNA Sequencer (A.L.F. DNA Sequencer;
LKB Pharmacia) operated by ALFwin
TM ver. 1.0 soft-
ware (Pharmacia). Fluorescence curve data were further
processed by P2 software. Exon inclusion was quantiﬁed
as the percentage of doubly spliced mRNA isoforms
relative to total mRNA in each sample. For quantiﬁcation
of 30 ss selectivity the ratio of 1.5.7- and 1.4a.7-mRNA in
each sample was calculated. The activation of 50 ss D4 was
quantiﬁed as the sum of the percentages of doubly and
singly spliced RNA using D4 (ss) relative to total mRNA
in each sample.
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Cell cultures were maintained in RPMI 1640 medium
containing 10% FCS (Pansystems GmbH) and antibiotics
(penicillin and streptomycin). Viral stocks were prepared
by transfecting 293T cells with the provirus expression
vector pNL4-3 followed by ELISA (Innotest HIV p24
Antigen mAB; Innogenetics N.V.) of culture supernatant
for p24 content. For HIV-1 infection 5 10
6 PM1 cells
were re-suspended in 500ml culture medium and incubated
at 378C for 3h with 100ng of the viral stock. After
infection, cells were washed twice with PBS without Ca
2+
and Mg
2+ and further cultured in 5ml medium for
another 5 days. Subsequently, total RNA was prepared
using Trizol reagent (Invitrogen) according to the protocol
provided by the manufacturer.
RESULTS
Individual SR protein-binding sites ofHIV-1 GAR
ESE synergistically increase recognitionof
alternatively spliced exonsflanked by D4
Previously we identiﬁed a purine-rich exonic splicing
enhancer (GAR ESE) located in the 50 part of HIV-1
exon 5 (28), which according to ESEﬁnder (34) consists of
two predicted SF2/ASF-binding sites, an SRp40 and an
SRp55-binding site (Figure 1). Both, puriﬁed SF2/ASF2
and SRp40 were shown to comparably restore in vitro
splicing of a GAR ESE-dependent heterologous dsx-
substrate in splicing-deﬁcient HeLa S100 extracts, while
the enhancer did not respond to SRp55 (22). However,
mutation of the predicted SRp40-binding site, in vitro as
well as in vivo, only slightly impaired splicing, while
mutation of both SF2/ASF-binding sites strongly reduced
activation of 50 ss D4 and the heterologous 30 ss,
respectively (22). Therefore, we set out to determine in
more detail the contribution of the SF2/ASF- and SRp40-
binding sites to the enhancer function. To investigate
whether a discrete modulation of exon 5 recognition could
be achieved by diﬀerent binding sites for SF2/ASF and
SRp40 of the GAR ESE, individual and combinatorial
binding site mutations were introduced into our pre-
viously described 2-intron HIV-1 minigene (pSV-1-env)
(Figure 2A and B). None of the binding site mutations
introduced into the reporter construct in this study
generated additional SR protein-binding site predictions
by the ESEﬁnder. RT–PCR analysis of transiently
transfected HeLa-T4
+ cells revealed that RNA from the
reporter construct is processed into several mRNA
isoforms thereby generating doubly spliced mRNA con-
taining an internal exon due to the activation of the
alternative 30 ss A5 (1.5.7) or A4a (1.4a.7), singly spliced
mRNA with the distal intron removed (ss), and to a lesser
extent unspliced mRNA (us) (Figure 2C, lane1).
Introducing mutations for all three predicted SR pro-
tein-binding sites completely abolished exon recognition
(Figure 2C, lane 2) underlining the essential role of the
GAR ESE for exon recognition in accordance with a
diﬀerent triple binding site mutation generated earlier
(Figure 2C, lane E). The strongest eﬀect of a single
binding site mutation on exon inclusion was exerted by
loss of the proximal SF2/ASF-binding site [SF2(1)] result-
ing in a decrease of exon inclusion from 88 to 49% and
concomitant exon skipping (Figure 2C and D, cf. lanes 1
and 8). Mutating either the distal SF2/ASF [SF2(2)] or the
SRp40-binding site alone only led to a slight decrease in
exon recognition of about 10% (Figure 2C and D, lanes 6
and 7). Combinatorial mutations of two of the SR
protein-binding sites, however, dramatically reduced
exon recognition to inclusion rates below 14% indepen-
dent of which site had been mutated. Together, these
results show that each SR protein-binding site of the GAR
ESE analysed here contributes to exon recognition.
Furthermore, we conclude that any two SR protein-
binding sites synergistically mediate exon recognition,
whereas the presence of the third only leads to an additive
eﬀect on exon recognition. These data also support our
previous observation that the GAR enhancer is essential
for eﬃcient internal exon recognition, which we showed
here to depend synergistically on all three binding sites for
SR proteins SF2/ASF and SRp40, with the proximal SF2/
ASF-binding site having the highest impact on the extent
of exon recognition.
The proximal SF2/ASF-binding site specifically
contributes to A5usage
Analysing the ratio of exon 5 to exon 4a inclusion, we
detected a dominant inﬂuence of the GAR ESE’s proximal
SF2/ASF-binding site [SF2(1)] on the eﬃciency of exon 5
recognition. In the parent reporter construct, exon 5 was
three times more frequently included than exon 4a, which
is comparable to the splicing pattern in HIV-1 NL4/3-
infected cells (data not shown). Irrespective of the overall
exon inclusion eﬃciency, mutation of SF2(1) led to a
decrease in exon 5 and a concomitant increase in exon 4a
recognition (Figure 2C and E, cf. lanes 1 and 8).
In contrast, mutation of the distal SF2/ASF- or SRp40-
binding site not only maintained this ratio but even
slightly increased A5 over A4a usage suggesting that the
distal SR protein-binding sites might preferentially acti-
vate A4a (Figure 2C and E, cf. lanes 1, 6 and 7). However,
combining the mutations of the proximal SF2/ASF and
one distal SR protein-binding site pronounced the
preferential activation of A4a rather than causing an
intermediate ratio of 30 ss activation (Figure 2C and E, cf.
lanes 4, 5 and 8). Besides its general enhancing role in
internal exon recognition this indicates that only the
proximal SF2/ASF-binding site confers selective activa-
tion of 30 ss A5. From these results we conclude that the
HIV-1 exon 5 GAR ESE fulﬁls a dual role in the
regulation of alternative splicing by (i) ensuring recogni-
tion of the alternative exons 5 and 4a and (ii) determining
the ratio of internal exon recognition in favour of exon 5.
Apredicted third SF2/ASF-binding site covering the
intron/exon 5border ensures preferential selection ofA5
RNA aﬃnity chromatography assays indicated that
inactivating the GAR ESE did not completely abolish
binding of SF2/ASF to the in vitro transcript (data not
shown). Analysis of the sequence upstream of the GAR
Nucleic Acids Research, 2008, Vol. 36, No. 5 1453ESE using the ESEﬁnder algorithm (34) predicted a
third SF2/ASF-binding site [SF2(3)] overlapping A5
(Figure 3A). To investigate whether this putative site
additionally contributes to 30 ss selection we mutated
SF2(3) at position+2 (A to C). Within the context of
the wild-type GAR ESE, this mutation abrogated the
preferential selection of A5 as evidenced by an equal
activation of A5 and A4a (Figure 3B and C, cf. lanes 1 and
2). To clarify if this newly identiﬁed SF2/ASF-binding site
fulﬁls a redundant function in the enhancer complex we
analysed its inﬂuence on the splicing pattern in presence
of a GAR ESE mutation (ESE-) leading to an increased
ratio of A4a to A5 usage. To this end, we used the triple
GAR ESE mutation that still facilitated residual exon
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Figure 2. The GAR ESE in exon 5 ensures internal exon recognition and supports A5 usage. (A) Schematic representation of the HIV-1 2-intron
RNA reporter construct: gag, pol, vif and vpr-coding regions were deleted from the genome of the isolate NL4-3 (upper panel) generating a 3-exon-2-
intron minigene (middle panel). The GAR enhancer in the 50 part of exon 5 consists of two SF2/ASF (black box) and an SRp40-binding site (white
box). Positions of RT–PCR primers are indicated by arrows. An enlargement of the 50 part of the internal exon 5 with the preceding intronic region
illustrates the organization of the alternative 30 ss cluster consisting of A4c, A4a, A4b and A5 and the mutations introduced in the GAR enhancer
(lower panel). LTR: long terminal repeat, SV40: SV40 early promoter, p(A): SV40 polyadenylation signal. (B) Scheme of single and combinatorial
SR protein-binding site mutations in the GAR ESE used in this assay. (C) RT–PCR analysis of the reporter transcripts and derivatives carrying
mutations in the GAR ESE. HeLa-T4
+ cells were transiently transfected with the RNA reporter construct pSV-1-env or mutant derivatives
[numbering according to (B)] and pXGH5. Total RNA was subjected to RT–PCR with the primers indicated in (A) (alternatively spliced RNA,
ASR) or with a primer pair speciﬁc for hGH-mRNA as control for transfection eﬃciency (hGH). PCR products were separated on a non-
denaturating polyacrylamide gel and stained with ethidium bromide. Asterisks denote heteroduplex PCR products as revealed by sequencing
emerging due to non-denaturating conditions. (D) Quantiﬁcation of internal exon recognition after SR protein-binding site mutations. PCR products
were labelled using a Cy5-modiﬁed 50 primer, separated on denaturating gels and detected by Automated Laser Fluorescence (ALF). Exon
recognition was quantiﬁed as percentage of doubly spliced mRNA using either A4a or A5 relative to total mRNA (sum of spliced and unspliced
mRNA isoforms) in each sample. Error bars indicate standard deviation from three independent experiments. (E) Quantiﬁcation of 30 ss usage in
doubly spliced mRNA. Raw data resulting from the transfection experiments shown in (D) were analysed regarding 30 ss selectivity, which is depicted
as ratio of doubly spliced 1.5.7- to 1.4a.7-mRNA.
1454 Nucleic Acids Research, 2008, Vol. 36, No. 5recognition (Figure 2, lane E and Figure 3, lane 3),
allowing the detection of increasing as well as decreasing
amounts of exon inclusion. Mutating SF2(3) in this
construct completely abolished exon recognition
(Figure 3B and D, lane 4), suggesting the non-redundant
function of the proximal SF2/ASF-binding site of the
GAR ESE and the additional upstream SF2/ASF-binding
site. These results indicate that SF2(3) is also part of the
GAR ESE complex regulating splicing of the 30 ss cluster
preceding exon 5.
GAR ESE-mediated 3’ ss selectivity is
augmented by U1 snRNPbinding at D4
We previously showed that besides activating splicing at
the upstream 30 ss the GAR ESE also recruits U1 snRNP
to the downstream 50 ss D4 (22). Since U1snRNP binding
at a downstream 50 ss has been shown to assist exon
recognition in general (35), we studied the role of cross-
exon interactions between U1 snRNP bound at D4 and
the 30 ss cluster in the preferential activation of A5. To
this end, we analysed, if increasing U1 snRNP-binding
stability shifted the mutationally induced preferential
activation of A4a back towards the dominant A5 usage
observed in the wild-type splicing reporter construct.
Preferential activation of A4a was again achieved by
introducing the triple SR-protein binding site mutation
into the GAR ESE, which still facilitated residual exon
recognition (Figure 4A, lane 2). Cotransfection of an
expression plasmid coding for an U1 snRNA with perfect
complementarity to D4 solely increased recognition of
internal exon 4a but failed to restore preferential 30 ss A5
usage (Figure 4A–C, cf. lanes 2 and 4). This indicates that
increased RNA duplex formation between U1 snRNA
and D4 only advanced overall exon recognition, while
preferential A5 selection was ensured by the GAR ESE.
As control, we also analysed the eﬀect of increasing U1
snRNP-binding stability on the ratio of A5 to A4a usage
in the presence of the wild-type GAR ESE. Because exon
recognition already predominates in the minigene con-
struct containing the GAR ESE and D4, we ﬁrst
inactivated D4 by introducing a point mutation at
position +3 from A to U. This mutation has been
shown to lower the complementarity of D4 to U1 snRNA,
thereby abrogating U1 snRNP binding, and can be
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Figure 4. GAR ESE-mediated 30 ss selectivity is augmented by increasing downstream U1 snRNP-binding stability. (A) Increasing U1 snRNP-
binding stability at D4 enhances 30 ss selectivity of the GAR ESE. RT–PCR analysis of RNA isolated from HeLa-T4
+ cells transiently transfected
with the 2-intron reporter constructs pSV-1-env (lane 1, D4 GAR), the enhancer mutant pSV-1-env SF2(1)
  SF2(2)
  SRp40
  (lanes 2 and 4, D4
ESE-), or a construct carrying a mutation in the 50 ss D4, pSV-1-env 3U (lanes 3, 5 and 6, 3U GAR). Endogenous U1 snRNA forms a consecutive
base pairing with 16H-bonds to the 50 ss in constructs containing D4 (left panel). Cotransfection of the U1 snRNA expression plasmid pUCBU1 6A
harbouring a compensatory mutation (lane 5) reconstitutes the base pairing of a mutated 50 ss compared to D4, while U1 snRNA expression
plasmids pUCBU1 9T10G11C (lane 4) or pUCBU1 6Apm (lane 6) even extend the base pairing to neighbouring nucleotides. The exon structure of
the alternatively spliced mRNAs (ASR) is indicated. RT–PCR analysis of hGH-mRNA was performed to monitor transfection eﬃciency.
(B) Quantiﬁcation of 30 ss selectivity in doubly spliced mRNA. 30 ss selectivity was calculated as ratio of 1.5.7- to 1.4a.7-mRNA. Error bars represent
standard deviation from three independent experiments. (C) Quantiﬁcation of exon inclusion. Raw data from the experiments in (B) were analysed
regarding the percentage of doubly spliced mRNA relative to total mRNA isoforms per sample. Error bars indicate standard deviation.
(D) Decreasing U1 snRNP-binding stability reduces 30 ss selectivity. HeLa-T4
+ cells were transfected with the 2-intron minigene reporter carrying the
wild-type 50 ss D4 (lane 1, pSV-1-env) or mutant 50 ss with reduced complementarity to the endogenous U1 snRNA (lane 2, pSV-1-env cs-2
14; lane 3,
pSV-1-env cs+1
12) as depicted on the left side. The exon structure of the mRNA is indicated at the right. The asterisk marks the inclusion of 13-nt
intronic sequence downstream of exon 5 due to activation of a cryptic 50 ss downstream of D4. RT–PCR analysis of hGH-mRNA controlled equal
transfection eﬃciency. (E) Quantiﬁcation of 30 ss selectivity as performed in (B). Error bars represent standard deviation from three independent
experiments. (F) Quantiﬁcation of exon inclusion. Raw data from the experiments in (E) were analysed as performed in (C). Error bars indicate
standard deviation.
1456 Nucleic Acids Research, 2008, Vol. 36, No. 5rescued upon cotransfection of a corresponding U1
snRNA expression plasmid carrying a compensatory
mutation (8,28). Inactivating D4 eliminated internal
exon recognition in the 2-intron minigene construct
(Figure 4A and C, lane 3). As expected, cotransfecting
plasmids expressing compensatory (high or full 50 ss com-
plementarity) U1 snRNAs rescued internal exon recogni-
tion (Figure 4A and C, lanes 5 and 6). However, as seen
before with the mutated GAR ESE, increasing U1 snRNP
binding solely augmented activation of the 30 ss selected by
the SR protein-binding sites of the GAR ESE (Figure 4B,
cf. lane 1 with 5 and 6). This conﬁrms that 30 ss selection
is exclusively determined by the GAR enhancer, while
U1 snRNP binding at the downstream 50 ss supports
the overall level of 30 ss selectivity by cross-exon
interactions.
Although increased U1 snRNP binding did not account
for 30 ss selectivity, it generally supported GAR ESE-
mediated 30 ss activation (Figure 4A and C, cf. lane 2 with 4
and 5 with 6). Substituting D4 with a weaker 50 ss of
intermediate complementarity to endogenous U1 snRNA
showed no eﬀect on 30 ss selection (Figure 4D, lane 2).
Surprisingly, introducing a low complementarity 50 ss
activated the previously identiﬁed cryptic 50 ss 13-nt down-
stream of D4 (36), leading to the inclusion of an additional
intronic sequence into exons 4a and 5 (Figure 4D, lane 3).
Introduction of this weak 50 ss resulted in a moderate
decrease in 30 ss selectivity (Figure 4E, lane 3). This demon-
strates that the degree of the GAR enhancer-mediated 30
ss selectivity depends on the stability of U1 snRNP binding
at the downstream 50 ss.
Taken together, these results show that speciﬁc 30 ss
selection is conferred by the GAR ESE, rather than by U1
snRNP-binding stability. Nevertheless, U1 snRNP bind-
ing at 50 ss D4 augments activation of the 30 ss cluster and
thereby enhances the 30 ss selecting mechanism presum-
ably through cross-exon interactions.
The 3’ partof exon5contains an additionalenhancer activity
The ﬁnding that U1 snRNP bound to the downstream 50 ss
of exon 5 takes part in the GAR ESE-mediated 30 ss
activation raised the question of whether the exonic
sequence located between the enhancer and D4, termed
E42, might be involved in the formation of the cross-exon
interactions. To investigate the impact of the E42 sequence
on exon recognition we analysed the splicing pattern of
the 2-intron minigene construct after either substituting
the E42 fragment with an HIV-1 control sequence of
identical length, which did not support U1 snRNP binding
at D4 (HIV#18) (22), or deleting E42 (E42). RT–PCR
analysis of transiently transfected HeLa-T4
+ cells revealed
that substituting the E42 sequence completely abolished
internal exon recognition (1.4a.7; 1.5.7) (Figure 5B and D,
cf. lanes 1 and 2) and, unexpectedly, also activation of
D4 resulting in the loss of singly spliced RNA [Figure 5C,
lane 2 (ss)]. This demonstrates that although E42 is
insuﬃcient to activate D4 by itself, the sequence is essential
to connect the activating eﬀect of the GAR enhancer to
the 50 ss. On the other hand, activation of D4 remained
after deletion of E42, while exon recognition was nearly
completely abolished resulting in the identiﬁcation of
mostly unspliced and singly spliced RNA using either
splicesitepairD1/A7(1.7)orD4/A7(ss)(Figure5CandD,
lane3).ThisshowsthattheGARESEinproximitytothe50
ss exclusively restored the enhancing function on D4
whereas internal exon recognition was only slightly
recovered by use of A4c, the most upstream 30 ss of the
cluster. Therefore, the GAR ESE when positioned directly
upstream of D4 enhances splicing at this 50 ss but failed to
eﬃciently activate any of the 30 ss simultaneously.
Although inhibitory elements in the substituted sequence
or exon length constraints cannot be ruled out formally,
we reasoned from this experiment that in addition to the
GAR enhancer the E42 sequence is essential for establish-
ing cross-exon interactions necessary for 50 ss activation
and eﬃcient exon recognition in completely spliced
mRNAs.
GAR ESEand binding ofU1 snRNP atD4 arenecessary
foractivation ofthe 3’ss cluster in Rev-dependent mRNAs
While the early phase of HIV-1 gene expression is marked
by complete intron removal from the RNA precursor, in
the intermediate and the late phase splicing at 50 ss D4 is
restrained by the interaction of the viral regulatory protein
Rev with the RRE. In order to examine the roles both of
the U1 snRNP binding at D4 and of the GAR enhancer
for activation of the 30 ss cluster during the late phase,
we used HeLa-T4
+ cells transiently cotransfected with the
2-intron splicing reporter construct and a Rev expression
plasmid. The relative amount of unspliced versus spliced,
but still intron-containing vpu/env-mRNA was detected by
RT–PCR.
To examine the inﬂuence of U1 snRNP binding at D4
on activation of the 30 ss cluster in the late phase, we
compared the wild-type 50 ss D4 with two mutations: 3U
abolishing U1 snRNA binding and GTV 15A restitution
of U1 snRNP binding but suppressing splicing at D4. The
3U-mutation led to complete loss of vpu/env-mRNA,
while the amount of unspliced mRNA remained
unchanged, demonstrating that none of the 30 ss in the
cluster upstream of exon 5 had been activated (Figure 6A,
cf. 3U versus D4). To conﬁrm that lack of detectability of
the vpu/env-mRNA was caused by loss of U1 snRNP
binding at D4, we reconstituted U1 snRNP binding by
substituting D4 with a splicing inactive U1 snRNP-
binding site (GTV) (28). The GTV sequence possesses
perfect complementarity to the 50 end of the U1 snRNA
except for position +1, which was mutated from G to C
to prevent splicing. After introduction of the GTV
sequence, splicing from a cryptic 50 ss 13-nt downstream
of the inactivated 50 ss (36) was observed (data not
shown). To exclude splicing of the downstream intron, we
additionally inactivated this cryptic 50 ss (GTV 15A).
Restitution of U1 snRNP binding rescued the expression
of vpu/env-mRNA to the same extent as observed with D4
(Figure 6A, cf. GTV 15A versus D4). From this experi-
ment we conclude that U1 snRNP binding at D4 is needed
for 30 ss activation for Rev-dependent mRNAs, although
D4 is not spliced itself.
Nucleic Acids Research, 2008, Vol. 36, No. 5 1457To examine the inﬂuence of GAR on activation of the
upstream 30 ss cluster in the late phase, we compared the
Rev-dependent splicing pattern of the subgenomic
splicing reporter construct with diﬀerentially mutated
GAR ESE versions. Simultaneous mutation of all three
SR protein-binding sites of the GAR enhancer abolished
expression of vpu/env-mRNA (data not shown). Since
individual SR protein-binding sites of the GAR ESE were
found to contribute diﬀerentially to its enhancer function
in completely spliced RNA, we also examined this
dependency in vpu/env-mRNA with constructs carrying
mutations in either one of the SR protein-binding sites.
Mutation of SF2(2) or the SRp40-binding site reduced
the vpu/env-mRNA expression about 2-fold [Figure 6B,
SF2(2)- and SRp40-], whereas mutating SF2(1) was
already suﬃcient to eliminate its expression [Figure 6B,
SF2(1)-]. In contrast, the amount of unspliced mRNA
remained unchanged for mutation of the SRp40-binding
site and even increased after mutation of any SF2/ASF-
binding site. This result indicates that the individual
SR protein-binding sites maintain their relative impact
on 30 ss activation in vpu/env-mRNA. Moreover, GAR
enhancer dependency may be stronger than in completely
spliced mRNA, since any single SR protein-binding site
mutation clearly reduces vpu/env-mRNA expression.
In conclusion, both the GAR ESE and U1 snRNP
binding at D4 are essential for activation of the 30 ss
cluster to generate vpu/env-mRNA in the intermediate and
late phases of viral gene expression.
DISCUSSION
In HIV-1 exon 5a purine-rich multisite exonic splicing
enhancer termed GAR ESE has been identiﬁed activating
both an upstream 30 ss as well as a downstream 50 ss
(22,28). In this work, we characterized the eﬀect of the
GAR ESE on simultaneous 30 ss and 50 ss activation,
which was demonstrated to be additionally dependent on
the interplay with downstream regulatory elements of
exon 5. We found that the GAR ESE performed a dual
splice regulatory function (i) by synergistically enhancing
inclusion of the internal exons 4a and 5 through all
identiﬁed SR protein-binding sites, and (ii) by speciﬁcally
activating A5 of the 30 ss cluster solely by the proximal
SF2/ASF-binding sites. Analysing the interaction of the
GAR ESE with U1 snRNP at the downstream 50 ss D4
and the E42 sequence located in between, we showed it to
be essential for activation and selectivity of the alternative
30 ss cluster, which in turn is necessary for generation of
rev-, nef- and vpu/env-mRNA in the early and late phases.
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Figure 5. The 30 part of HIV-1 exon 5 mediates an additional enhancer function. (A) The schematic depicts the elements in the central exon 5 of the
2-intron minigene reporter and mutant constructs. The E42 fragment in 30 part of exon 5 has either been substituted for a control HIV-1 sequence
(HIV#18) or deleted (E42). (B) RT–PCR analysis of RNA from HeLa-T4
+ cells transiently transfected with the 2-intron reporter construct
pSV-1-env (E42), the reporter construct with a substitution (HIV#18) or the deletion of the E42 sequence (E42). RT–PCR was performed for
alternatively spliced reporter RNA (ASR) and the control hGH-mRNA (hGH). us: unspliced, ss: singly spliced. (C) Quantiﬁcation of D4 activation.
The sum of doubly and singly spliced RNA using D4 (ss) was calculated relative to total mRNA per sample. Error bars indicate standard deviation
from three independent experiments. (D) Quantiﬁcation of exon inclusion. Raw data from the experiments in (C) were analysed regarding the
percentage of doubly spliced mRNA using A5, A4a or A4c relative to total mRNA isoforms per sample. Error bars represent standard deviation.
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Figure 6. GAR ESE and U1 snRNP binding at D4 are necessary for activation of the 30 ss cluster in vpu/env-mRNA. (A) RT–PCR analysis of RNA
from HeLa-T4
+ cells transfected with the 2-inton reporter construct carrying wild-type D4 (D4), a mutant unable to stably bind endogenous U1
snRNA (3U) or a splicing-deﬁcient U1 snRNP-binding site with the additional mutation of the cryptic 50 ss downstream (GTV 15A). Cells were
cotransfected with SVcrev, an expression plasmid for the viral regulatory protein Rev, allowing the export of intron-containing reporter mRNA into
the cytoplasm, and with pXGH5. Base pairings between D4 and the splice site mutants 3U and GTV 15A are denoted at the upper panel. The star
marks the additional mutation of the cryptic 50 ss 13-nt downstream of D4 (36). RT–PCR was performed using a Cy5-labelled 50primer, separated on
denaturating gels and detected by (ALF). The RT-PCR products are shown as processed ﬂuorescence curve data of the electrophoretic separation.
The alternative spliced mRNA isoforms are depicted above the lanes. The asterisk marks an RNA signal, which was identiﬁed as unspeciﬁc signal by
sequencing. (B) RT–PCR analysis of RNA from HeLa-T4
+ cells transiently transfected with the wild-type reporter construct or constructs carrying a
single SR protein-binding site (cf. Figure 2A) as indicated in the respective lanes, the Rev-expression plasmid SVcrev and pXGH5. Cy5-labelled
RT–PCR products were analysed by ALF.
Nucleic Acids Research, 2008, Vol. 36, No. 5 1459While most of the HIV-1 pre-mRNA sequence is
removed by extensive splicing in the early phase of viral
gene expression, the internal exons 4c, 4a, 4b and 5 have
been described to be frequently included into the 1.8-kb
mRNA class due to activation of the respective alternative
30 ss and the 50 ss D4 (7). Our results evidence that the
three SF2/ASF and SRp40-binding sites of the GAR ESE
(22) individually contribute to the recognition of the
internal exons 4a and 5 in a 2-intron minigene reporter
whose splicing pattern was comparable to the respective
splicing pattern of HIV-1 NL4/3-infected PM1 cells.
The individual SR protein-binding sites diﬀered in their
extent of activating exon recognition [SF2(1)>SF2(2)
>SRp40], albeit at a rather low overall level. However,
the combination of two SR protein-binding sites in the
GAR enhancer complex synergistically activated exon
recognition way beyond the sum of the individual
contributions, while addition of a third binding site only
slightly increased exon recognition. Two SF2/ASF pro-
tein-binding sites mediated the inclusion of the internal
exons 4a and 5 to a similar extent as an SRp40- and an
SF2/ASF-binding site, which is in line with the ﬁnding
that the RS domains are interchangeable between diﬀerent
SR proteins for some enhancer functions (37,38).
Synergy in regulatory processes, like e.g. alternative
splice site activation, has been proposed to be mediated
either by cooperative binding of regulatory factors to
enhancer sequences or by enhancement of two or more
ineﬃcient steps of the regulated process by direct
interactions (39). Analysing the function of the GAR
ESE, we found that any single SR protein-binding site was
already suﬃcient for sole activation of 50 ss D4, but not for
exon inclusion, suggesting downstream directed cross-
exon interactions of the GAR enhancer. Since we did not
observe any synergistic enhancement of splicing at D4 in
the presence of two or more SR protein-binding sites of
the GAR ESE, it seems highly unlikely that its synergistic
eﬀect on exon recognition is mediated through coopera-
tive binding of SR proteins, as has been found in the
Drosophila doublesex repeat element (40,41). In our
previous work, the individual SR protein-binding sites of
the downstream GAR ESE showed no synergistic eﬀect
on activation of a heterologous 30 ss (22). We thus
hypothesize the synergy found in exon recognition to stem
from simultaneous interactions with the 30 ss and 50 ss,
emanating from the enhancer into opposite directions, and
thereby promoting diﬀerent steps in the spliceosome
assembly at the respective upstream and downstream
intron (cf. Figure 7). Such synergistic action is not
automatically associated with every bidirectional enhancer
(42) and may hint to diﬀerent mechanisms than present
in cases of additive enhancer action. Synergy in complex
assembly has been implicated as molecular switch for
regulatory processes (39). The synergistic activation of
internal exon inclusion by the three distinct binding sites
for the SR proteins SF2/ASF and SRp40 of the GAR ESE
might allow the virus to switch from the shortest
nef1-mRNA isoform, consisting only of the terminal
E42
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Figure 7. Model of interactions causing splice site activation in the internal HIV-1 exon 5. (A) The GAR ESE activates the 50 ss presumably via a yet
unknown factor x. Subsequent U1 snRNP binding in turn activates the GAR ESE, which mediates general activation of the 30 ss cluster. (B) Besides
the downstream interactions the GAR ESE speciﬁcally activates A5 by the proximal SF2/ASF-binding sites.
1460 Nucleic Acids Research, 2008, Vol. 36, No. 5exons 1 and 7 of the HIV-1 pre-mRNA, to internal exon-
containing mRNAs coding for the regulatory proteins Rev
or Nef.
Our model of activation through oppositely directed
interactions originating from the GAR ESE is supported
by the additional requirement of the E42 sequence, located
between the enhancer and D4, for internal exon recogni-
tion in the subgenomic 2-intron minigene construct.
As E42 failed to initiate U1 snRNP binding at the 50 ss
in the absence of the GAR enhancer (22), we assumed
that it recruits a yet unidentiﬁed factor to mediate the
GAR-dependent activation of D4. This factor might either
act indirectly by facilitating cross-exon interactions
between the GAR ESE-bound SR proteins and U1
snRNP, or establish an independent additional weak
interaction with the U1 snRNP providing the stabilization
necessary to activate D4. The importance of this element
for recognition of the short HIV-1 exon 5, ﬂanked by long
introns, supports the model that recognition is predomi-
nantly promoted by interactions of proteins across the
exon (43–45).
Unbalanced activation of the competitive 30 ss A4a and
A5 has also been observed during viral gene expression
and revealed a considerably higher expression of mRNAs
using A5 than any other 30 ss of the cluster (7), leading
to Nef-encoding mRNA required in the early phase of
viral gene expression. Nef fulﬁls a number of regulatory
functions during viral replication, e.g. cellular surface
receptor down-modulation (46), which are executed
through mostly weak interactions of distinct Nef domains
with a variety of cellular proteins (47). An elevated
Nef concentration in the infected cell might thus
contribute to eﬃcient viral replication. Increased inclusion
of the alternative internal exon 5 compared to exon 4a, as
detected in our experiments, may thus lend a further
functionality to the GAR enhancer for viral replication.
SR proteins are likely to mediate the function of the
GAR ESE through their RS domains, which are known to
interact with proteins and have more recently been shown
to also stabilize double-stranded pre-mRNA-U snRNA
intermediates during spliceosomal assembly (26,27). Both
protein–protein and RNA–protein interactions might
be involved in the 30 ss selectivity of the GAR ESE.
An interaction of an RS domain with double-stranded
RNA might depend on their stereo-speciﬁc arrangement,
and might therefore be restricted to the proximal
SF2/ASF-binding sites. In contrast, protein–protein inter-
actions between the RS domains and proteins of the
splicing machinery might be less reliant on stereo-speciﬁc
requirements, and thereby might act more uniformly on
the whole 30 ss cluster.
The extent of 30 ss selectivity mediated by the GAR
enhancer was shown to be decreased by weakening the
interaction of U1 snRNP with the 50 ss D4, leading to
more uniform 30 ss activation. This additionally supports
that U1 snRNP binding participates in 30 ss activation
through cross-exon interactions, presumably by stabilizing
a speciﬁc 30 ss selecting SR protein conﬁguration at the
GAR enhancer.
Besides its function in the intronless 1.8-kb mRNA
class, we present evidence that U1 snRNP binding at D4 is
absolutely required also for activation of the 30 ss cluster
in Rev-dependent 4-kb vpu/env-mRNAs, which are not
spliced at D4. Since we detected equal amounts of
unspliced RNA for several mutations of D4, we assume
that in the context of the additional upstream 50 ss D1, U1
snRNP binding at D4 is needed for 30 ss activation rather
than for transcript stability (28,48).
In the vpu/env-mRNAs the 30 ss activation ratio of A5
over A4a exceeded that of the 1.8-kb mRNAs, as has been
described for viral infection (7). Since U1 snRNP is not
displaced from D4 in the 4-kb mRNA class, its upstream-
directed cross-exon interactions are likely to persist
longer, mediating the pronounced 30 ss selectivity of the
GAR ESE. Thereby the GAR ESE might contribute to
the preferential generation of the vpu/env-mRNA isoforms
eﬃciently expressing Vpu (1), which has been shown to
support viral replication.
This work demonstrates that the GAR ESE constitutes
a complex substantial splicing regulatory element
throughout HIV-1 gene expression. The GAR ESE has
recently been successfully targeted to inhibit HIV-1
multiplication (49), and further insights regarding the
mechanism of GAR ESE-mediated splice site activation
and selectivity might create new strategies to speciﬁcally
inhibit generation of essential regulatory HIV-1 mRNAs.
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